Clinical Trial Update: Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating WH002 as neoadjuvant chemotherapy in women with HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• WH002

Snippet

Sponsor: Beijing Wehand-Bio Pharmaceutical Co., Ltd | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED